Total
0
Shares
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: Little Green Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has exported over 1000 units of medicinal cannabis oil to the U.K. as part of consignment sales agreement with LYPHE Group
  • LYPHE has a significant presence in the United Kingdom and writes over half of all new medicinal cannabis prescriptions
  • As part of the agreement, LYPHE will prescribe and dispense the company’s medicinal cannabis products to patients while reporting the efficacy, safety and patient outcomes
  • This deal is significant as it further cements Little Green Pharma’s presence in the U.K. and European markets
  • Furthermore, it expects to ship its first export order to Germany by the December quarter
  • Company shares are up a slight 2.82 per cent and are trading for 36.5 cents each

Little Green Pharma (LGP) has exported over 1000 units of medicinal cannabis oil to the U.K. as part of consignment sales agreement with LYPHE Group.

LYPHE is the parent company of Astral Health, to whom the company delivered a pathfinder shipment in mid-April.

Importantly, LYPHE has a significant presence in the United Kingdom and writes over half of all new medicinal cannabis prescriptions in the nation.

Under the sales agreement, LYPHE will prescribe and dispense Little Green Pharma’s medicinal cannabis products to patients at its clinics. Simultaneously, LYPHE will be responsible for reporting data investigating efficacy, safety, quality of life, and patient-reported outcomes to Little Green Pharma.

Despite sales and revenue having a small chance of being financially material, this shipment represents a key step towards the company’s goal of meeting the growing demand by patients wanting access to medicinal cannabis in the U.K. and across Europe.

Little Green Pharma expects it will receive its expanded Cultivation and Production Permit shortly. This permit will provide further cultivation capacity to help it meet the demand in the U.K. and Europe.

Furthermore, LGP anticipates making its first export of medicinal cannabis products to Germany by the December quarter.

Company shares are up a slight 2.82 per cent and are trading for 36.5 cents each at market close.

LGP by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.